Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest Selective internal radiation therapy Stories

2013-07-10 04:20:41

LONDON, July 10, 2013 /PRNewswire/ -- A decade ago, there was little interest in interventional cancer therapies. Five years ago, newly diagnosed cases of different types of cancer stood at about 12.7 million with 7.6 million related deaths registered. According to the WHO GLOBOCAN database, the top three diagnosed cancer forms in 2008 included lung - 1.61 million, breast - 1.38 million, and colorectal - 1.23 million, while the most common types of cancer with leading death rate were...

2013-06-24 12:25:33

PARIS, June 24, 2013 /PRNewswire/ -- Launched by the Assistance Publique - Hopitaux de Paris (AP-HP) in December 2011, SARAH, a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma seeks to enroll 400 patients To date, more than 150 patients have taken part in this study PARIS (June 20, 2013) In...

2013-06-20 12:31:16

BOLOGNA, Italy, June 20, 2013 /PRNewswire/ -- Based on New Data from Multi-Centre ENRY Evaluation of 325 Patients, Authors Suggest that Radioembolisation May Be a Well-Tolerated and Effective Option for an Increasing Population of Older Patients Results of a new analysis by members of the multi-centre European Network on Radioembolisation with Yttrium-90 Resin Microspheres (ENRY), published on-line in the Journal of Hepatology, the...

2013-05-16 23:31:08

INTIO's TipTRAC will be demonstrated at the World Congress of Interventional Oncology. Real-time visualization of probe placement enhances the interventional radiologist's ability to more accurately deliver ablative therapy. New York, NY (PRWEB) May 16, 2013 INTIO, Inc. is introducing TipTRAC, a new and significant feature of its 510(k) cleared ClearStart SVM system at the World Congress of Interventional Oncology in New York, May 16-19, 2013. TipTRAC, used in CT-guided ablative therapies,...

2013-03-06 08:25:56

WESTMINSTER, Colo., March 6, 2013 /PRNewswire/ -- Surefire Medical's new infusion system maximizes delivery of drugs directly to the tumor site while minimizing potential damage to non-target organs, according to a new study. The ability to more safely and efficiently deliver embolic agents to target tumors locally marks a significant advance in radiation oncology procedures and in the treatment of liver cancer. The 29 procedure study, led by Steven Rose, M.D. of the University of...

2012-12-11 04:21:35

SYDNEY, December 11, 2012 /PRNewswire/ -- http://www.sirtex.com informs doctors, patients and investors about the world's most widely used and widely studied form of SIRT for all cancers in the liver Sirtex today unveiled http://www.sirtex.com, a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining...

2012-09-04 18:21:24

WESTMINSTER, Colo., Sept. 5, 2012 /PRNewswire/ -- European regulators have approved Surefire Medical's Surefire Infusion System, a next generation device for chemo- and radioembolization procedures. The Colorado-based medical device company today announced that it is launching this product in the European market immediately. "Surefire Medical developed this ground-breaking technology to provide interventional radiologists with improved embolization certainty during their infusion...

2012-03-23 06:22:34

ORLANDO, March 23, 2012 /PRNewswire/ -- New Australian Data Provides Further Evidence of Survival Benefit for Radioembolisation Findings from the largest comparative multi-centre study performed to date using radioembolisation report a significantly prolonged survival benefit following SIR-Spheres microspheres in patients with treatment-refractory liver tumours from colorectal and other cancers. The results of the study were presented today at the 65th Annual Cancer...

2012-02-03 01:00:00

PARIS, February 3, 2012 /PRNewswire/ -- 'SARAH' - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment The start of SARAH, a new randomized controlled trial to directly compare the effectiveness of radioembolization with yttrium-90 resin microspheres (SIR-Spheres(R) microspheres; Sirtex Medical...

2011-08-16 07:40:00

Corporate Pledge of $50,000 Supports Major Fund-raising Initiative to Expand Minimally Invasive Medicine Into New Areas of Discovery FAIRFAX, Va., Aug. 16, 2011 /PRNewswire-USNewswire/ -- The Society of Interventional Radiology Foundation's Discovery Campaign, which seeks to further the growth of minimally invasive medicine into new areas of discovery, announced a major corporate pledge to that initiative. Sirtex Medical Inc.--a medical devices company that researches, develops and brings...